PMID- 31691101
OWN - NLM
STAT- MEDLINE
DCOM- 20200409
LR  - 20221207
IS  - 2008-2231 (Electronic)
IS  - 1560-8115 (Print)
IS  - 1560-8115 (Linking)
VI  - 27
IP  - 2
DP  - 2019 Dec
TI  - Effect of probiotics supplementation on glucose and oxidative stress in type 2 
      diabetes mellitus: a meta-analysis of randomized trials.
PG  - 827-837
LID - 10.1007/s40199-019-00302-2 [doi]
AB  - PURPOSE: The role of oxidative stress in pathogenesis of diabetes is well 
      established. In addition, an association between gut microbiota and type 2 
      diabetes mellitus (T2DM) is widely observed in previously published reports. This 
      meta-analysis critically examines the association between gut microbiota, and 
      oxidative stress in T2DM. METHODS: A systematic search for clinical trials was 
      performed in PubMed, Web of Science and Scopus web databases up to 1 Jan 2019. 
      Primary search terms include "microbiota", "diabetes", and "oxidative stress". 
      Study was conducted according to the Preferred Reporting Items for Systematic 
      reviews and Meta-Analyses (PRISMA) guideline. All clinical trials that compared 
      the effects of probiotic supplementations with a control group using end points 
      serum levels of fasting blood sugar (FBS), hemoglobin A1C (HbA1C) and oxidative 
      stress biomarkers were included. Two independent researchers screened the data 
      extracted from the relevant studies. The pooled standardized mean difference 
      (SMD) was estimated using the random or fixed effects model. Heterogeneity among 
      the studies was assessed using Q-test. RESULTS: Overall, 13 randomized clinical 
      trials (RCTs) involving 840 subjects with T2DM were included in the 
      meta-analysis. The analysis showed that probiotics intake resulted in significant 
      improvement in serum levels of FBS [SMD: -0.35, 95% CI: (-0.59, -0.12)], total 
      antioxidant status (TAS) [SMD: 0.33, 95% CI: (0.11, 0.55)], total glutathione 
      (GSH) [SMD: 0.41, 95% CI: (0.26, 0.56)] and malondialdehyde (MDA) [SMD: -0.54, 
      95% CI: (-0.83, -0.26)]. No significant improvement was found in HbA1C [SMD: 
      -0.06, 95% CI:(-0.82, 0.69)], and nitric oxide (NO) [SMD:-0.24, 95% CI:(-1.10, 
      0.62)] levels. CONCLUSION: It seems that gut microbiota can exert beneficial 
      effects in diabetic patients via altering oxidative stress' biomarkers. The 
      beneficial effect of gut microbiota however was modest on FBS and non-significant 
      on HbA1C. These results need to be confirmed by conducting more reliable RCTs. 
      PROSPERO REGISTRATION NUMBER: CRD42019134905. Graphical abstract Flow diagram of 
      the study selection process.
FAU - Ardeshirlarijani, Edris
AU  - Ardeshirlarijani E
AD  - Simon Fraser University, Burnaby, Canada.
FAU - Tabatabaei-Malazy, Ozra
AU  - Tabatabaei-Malazy O
AD  - Non-Cummunicable Diseases Research Center, Endocrinology and Metabolism 
      Population Sciences Institute, Tehran University of Medical Sciences, Tehran, 
      Iran.
AD  - Endocrinology and Metabolism Research Center, Endocrinology and Metabolism 
      Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Mohseni, Shahrzad
AU  - Mohseni S
AD  - Endocrinology and Metabolism Research Center, Endocrinology and Metabolism 
      Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Qorbani, Mostafa
AU  - Qorbani M
AD  - Non-communicable Diseases Research Center, Alborz University of Medical Sciences, 
      Karaj, Iran.
FAU - Larijani, Bagher
AU  - Larijani B
AD  - Endocrinology and Metabolism Research Center, Endocrinology and Metabolism 
      Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. 
      emrc@tums.ac.ir.
FAU - Baradar Jalili, Reza
AU  - Baradar Jalili R
AD  - Department of Surgery, University of British Columbia, Vancouver, British 
      Columbia, Canada.
LA  - eng
GR  - 39856-192-03-97/Tehran University of Medical Sciences & health services/
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20191105
PL  - Switzerland
TA  - Daru
JT  - Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences
JID - 101125969
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 31C4KY9ESH (Nitric Oxide)
SB  - IM
MH  - Blood Glucose/*drug effects
MH  - Diabetes Mellitus, Type 2/*diet therapy/metabolism
MH  - Gastrointestinal Microbiome/drug effects
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Nitric Oxide/metabolism
MH  - Oxidative Stress/*drug effects
MH  - Probiotics/pharmacology/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
PMC - PMC6895351
OTO - NOTNLM
OT  - Diabetes mellitus type 2
OT  - gut microbiota
OT  - oxidative stress
COIS- The authors declare that they have no conflict of interest.
EDAT- 2019/11/07 06:00
MHDA- 2020/04/10 06:00
PMCR- 2020/11/05
CRDT- 2019/11/07 06:00
PHST- 2019/08/02 00:00 [received]
PHST- 2019/09/18 00:00 [accepted]
PHST- 2019/11/07 06:00 [pubmed]
PHST- 2020/04/10 06:00 [medline]
PHST- 2019/11/07 06:00 [entrez]
PHST- 2020/11/05 00:00 [pmc-release]
AID - 10.1007/s40199-019-00302-2 [pii]
AID - 302 [pii]
AID - 10.1007/s40199-019-00302-2 [doi]
PST - ppublish
SO  - Daru. 2019 Dec;27(2):827-837. doi: 10.1007/s40199-019-00302-2. Epub 2019 Nov 5.